The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA ...

Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...

Six-year-old Hassan Abed Raboh lives with an excruciating bladder condition that 25 operations at Gaza hospitals could not ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...